Home
About Us
Products
Manus Aktteva Biopharma LLP, an ISO 9001: 2008 certified sourcing & export concern takes pride in fulfilling your requirements of Nutraceuticals, Specialty Chemicals, Pharmaceutical APIs and their advance level intermediates from ISO Certified, GMP, CGMP & USFDA approved units with supportive regulatory documentations like DMF, EDMF, COS, USDMF etc. We wish to state that anyone interested in sourcing any special molecules, APIs, Intermediates, Chiral Compounds etc. and feels it is difficult for early completion of tasks, please call on us and TEST US TO GET THE BEST OF US.
Category
Recommended
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
Enquiry
Quick Links
Blog
Contact Us

Zolmitriptan (CAS No.: 139264-17-8)

Manus Aktteva Biopharma LLP, a global supplier of Zolmitriptan, 139264-17-8 offers for your requirements of RND / Development quantities or commercials, based on status of the product. We can also offer its intermediates with supportive technical package required for evaluation.

CAS number:

139264-17-8

Chemical Name:

(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one, Zolmitriptan (CAS No.: 139264-17-8)

Pharmacopeia:

USP, EP, In House

Certificate:

GMP, cGMP, EUGMP, WHO GMP, ISO Certified, USFDA, Cofepris Mexico, Korea FDA

Application:

For R&D Purpose

Properties
Related Intermediates

Synonym

(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one, Zolmitriptan (CAS No.: 139264-17-8)

Molecular Formula

C16H21N3O2

Molecular Weight

287.36

Specifications

Available on request

Packing

Export worthy packing

Material Safety Data Sheet

Available on request

Availability

FOR R&D PORPOSE ONLY

Comments

Zolmitriptan : Anti Migraine - Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension.

Product Name	CAS No.
(S)-4-(4-Aminobenzyl)-2(1H)-oxazolidinone	152305-23-2	View \| Inquire
L-4-Nitrophenylalanine methyl ester hydrochloride	17193-40-7	View \| Inquire
(S)-4-Benzyl-2-oxazolidinone	90719-32-7	View \| Inquire
(S)-4-(4'-Nitrobenzyl)-1,3-oxazolidine-2-one	139264-66-7	View \| Inquire
4,4-Diethoxy-N,N-dimethyl-1-butanamine	1116-77-4	View \| Inquire
Sodium 4-chloro-1-hydroxybutanesulfonate	54322-20-2	View \| Inquire
4-Nitro-L-phenylalanine monohydrate	207591-86-4	View \| Inquire

Description:

Zolmitriptan : Anti Migraine - is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.

Documentation / Approvals :

USDMF	EDMF	CEP / COS	DMF (OPEN PART)	TDP	DMF - CTD	ICH

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
Products falling in to controlled substance category / list of schedule drugs shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
Manus Aktteva Biopharma LLP assumes no responsibility/liability in case of being imparted with goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual. Manus Aktteva makes no representations or warranties of any kind, express or implied, about the originality or reliability with respect to the intellectual property which includes patents in its products or services for any purpose.
Manus Aktteva Biopharma LLP warns the sellers not to sell any goods which infringe intellectual property in any manner whatsoever which includes patent rights of any individual.
Manus Aktteva Biopharma LLP warns the buyers not to use/procure any goods to achieve a product which might be knowingly causing an infringement of intellectual property in any manner whatsoever which includes patent rights of any individual.

Are you looking for Zolmitriptan (CAS No.: 139264-17-8) with documentation like PMDA - JAPAN, DMF - CANADA, TGA - AUSTRALIA, DMF (CLOSED PART), MHRA - UK, DMF - KOREA, AIFA - ITALY, MEDSAFE - NEW ZEALAND, HEALTH CANADA, JDMF, JAPAN - AFM, DCGI, COPP, TDMF, Written Confirmation? Please click here to send us sourcing request.

Why Us